0.72
+0.0094(+1.32%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.75 |
| Day High | 0.75 |
| Day Low | 0.69 |
| 52-Week High | 1.99 |
| 52-Week Low | 0.54 |
| Volume | 447,504 |
| Average Volume | 263,130 |
| Market Cap | 55.27M |
| PE | -1.41 |
| EPS | -0.51 |
| Moving Average 50 Days | 0.79 |
| Moving Average 200 Days | 0.92 |
| Change | 0.01 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $61.84 as of September 29, 2025 at a share price of $0.719. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $46.7 as of September 29, 2025 at a share price of $0.719.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
GlobeNewswire Inc.
7 hours ago
Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company Cu
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
GlobeNewswire Inc.
Aug 13, 2025 12:00 PM GMT
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing